7-year follow-up after stereotactic ablative radiotherapy for patients with stage I non-small cell lung cancer: Results of a phase 2 clinical trial.
Bing SunEric D BrooksRitsuko U KomakiZhongxing LiaoMelenda D JeterMary F McAleerPamela K AllenPeter A BalterJames D WelshMichael S O'ReillyDaniel GomezStephen M HahnJack A RothReza J MehranJohn V HeymachJoe Y ChangPublished in: Cancer (2017)
With long-term follow-up, the results of the current prospective study demonstrated outstanding local control and low toxicity after SABR in patients with clinical stage I NSCLC. Regional disease recurrence and distant metastases were the dominant manifestations of failure. Surveillance for second primary lung carcinoma is recommended. Cancer 2017;123:3031-39. © 2017 American Cancer Society.